Early Phase 1 Breast Cancer Trial, Recruiting NCT05659797 Sponsor: Abramson Cancer Center at Penn Medicine Condition: Breast Cancer
Back to Breast Cancer

Early Phase 1 Breast Cancer Trial, Recruiting

NCT05659797
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older.
  • People who have been diagnosed with breast cancer that is oestrogen receptor (ER) positive, confirmed by a laboratory test.
  • People who have at least one tumour or lesion measuring 1.0 cm or larger that has been detected on a standard scan such as a mammogram, ultrasound, MRI, CT, or PET/CT scan.
  • People who are willing to be informed about the research nature of this study and sign a written consent form before any study procedures begin.

Who may not be able to join:

  • People who are pregnant or breastfeeding (a pregnancy test will be carried out before any imaging for women who could potentially become pregnant).
  • People who, in the opinion of the study doctor or treating physician, would not be able to tolerate the imaging procedures involved in the study.
  • People who are currently taking tamoxifen or raloxifene.
  • People who have a medical condition, illness, or disorder that a study physician considers could put their safety at risk or prevent them from fully participating in the study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Principal Investigator: Christine Edmonds, MD, Abramson Cancer Center at Penn Medicine

Phone: 2155736569

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Sponsor
Abramson Cancer Center at Penn Medicine
Registry
ClinicalTrials.gov
Start date
2 October 2023
Est. completion
1 January 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Uptake of FES on BPET; Image quality; Image artifacts; Parenchymal appearance; Tumor size and extent

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov